The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Is The Expected Market Size Of The Acute Care Syndromic Testing Market From 2026 To 2030?
The market size for acute care syndromic testing has seen substantial growth in recent years. This sector is expected to expand from $4.59 billion in 2025 to $5.17 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.8%. Historically, this market expansion can be linked to the demand for emergency infection diagnosis, the growth of hospital intensive care units, initiatives for outbreak preparedness, the adoption of molecular diagnostics, and optimization of critical care workflows.
The acute care syndromic testing market is projected for substantial expansion over the upcoming years. It will grow to $8.3 billion in 2030 at a compound annual growth rate (CAGR) of 12.5%. This anticipated growth during the forecast period is largely due to factors such as AI-enabled syndromic panels, the broadening of emergency testing, antimicrobial stewardship programs, point-of-care molecular systems, and an increased focus on pandemic preparedness. Key trends anticipated during this period encompass rapid multiplex pathogen detection, molecular testing within emergency departments, multi-disease panels utilizing single samples, expedited clinical decision support, and a reduction in diagnostic turnaround time.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
What Major Drivers Are Influencing Demand In The Acute Care Syndromic Testing Market?
The acute care syndromic testing market is projected to be propelled by the increasing occurrence of infectious diseases. These diseases are illnesses caused by harmful microorganisms such as bacteria, viruses, fungi, or parasites that have the ability to spread from person to person, animals, or the environment. The rising incidence of infectious diseases is fueled by elements such as population growth, urbanization, global travel, antimicrobial resistance, and climate change, thereby escalating the demand for effective prevention and treatment. Acute care syndromic testing is employed in infectious diseases for the rapid identification of pathogens and co-infections through multiplex molecular diagnostics, which facilitates targeted treatment decisions. For instance, in February 2024, according to the Health Security Agency, a UK-based government agency, during week 4 of 2024, the influenza positivity rate saw an increase to 16.6%, rising from 14.0% in the preceding week. Influenza-like illness (ILI) consultations also experienced a rise, reaching 9.8 per 100,000 people, up from 7.5 per 100,000 in the prior week. Additionally, influenza hospitalizations ascended to 7.63 per 100,000, an increase from 5.12 per 100,000 the week before. Thus, the escalating incidence of infectious diseases is a key driver for the acute care syndromic testing market.
Which Segments Are Included In The Analysis Of The Acute Care Syndromic Testing Market?
The acute care syndromic testing market covered in this report is segmented –
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
Which Trends Are Impacting The Growth Of The Acute Care Syndromic Testing Market?
Major companies engaged in the acute care syndromic testing market are concentrating on technological innovations, such as multiplex real-time polymerase chain reaction (PCR) technology. This strategic focus aims to improve diagnostic precision, facilitate rapid pathogen identification, optimize laboratory workflows, reduce result turnaround times, and ultimately enhance patient outcomes through accurate and prompt treatment. Multiplex real-time PCR technology represents an advanced molecular diagnostic method capable of simultaneously detecting and quantifying multiple pathogens or genetic targets within a single PCR reaction, thereby boosting the efficiency and accuracy of disease diagnosis. For instance, in April 2023, QIAGEN N.V., a Netherlands-based biotechnology research firm, introduced its QIAstat-Dx syndromic testing solution in Japan. This solution incorporates a SARS-CoV-2 respiratory panel that can identify over 20 pathogens from a single sample. Leveraging multiplex real-time PCR technology, the system provides quick results with minimal labor compared to performing individual PCR assays. Its availability in over 100 countries globally significantly improves the accessibility of syndromic testing worldwide.
Which Key Industry Participants Are Active In The Acute Care Syndromic Testing Market?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
Read the full acute care syndromic testing market report here:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
Which Region Shows The Strongest Potential For Future Growth In The Acute Care Syndromic Testing Market?
North America was the largest region in the acute care syndromic testing market in 2025. The regions covered in the acute care syndromic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Acute Care Syndromic Testing Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp
Browse Through More Reports Similar to the Global Acute Care Syndromic Testing Market 2026, By The Business Research Company
Tele Intensive Care Market Report 2026
https://www.thebusinessresearchcompany.com/report/tele-intensive-care-global-market-report
Severe Acute Respiratory Syndrome Treatment Market Report 2026
Tele Intensive Care Unit Market Report 2026
https://www.thebusinessresearchcompany.com/report/tele-intensive-care-unit-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model